110 related articles for article (PubMed ID: 38199284)
21. Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial.
Murthy V; Maitre P; Bhatia J; Kannan S; Krishnatry R; Prakash G; Bakshi G; Pal M; Menon S; Mahantshetty U
Radiother Oncol; 2020 Apr; 145():71-80. PubMed ID: 31923712
[TBL] [Abstract][Full Text] [Related]
22. Rectal function following prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Galbreath RW; Blatt H; Lief JH
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):667-74. PubMed ID: 11020562
[TBL] [Abstract][Full Text] [Related]
23. Patient-reported persistent symptoms after radiotherapy and association with quality of life for prostate cancer survivors.
Spampinato S; Rancati T; Waskiewicz JM; Avuzzi B; Garibaldi E; Faiella A; Villa E; Magli A; Cante D; Girelli G; Gatti M; Noris Chiorda B; Rago L; Ferrari P; Piva C; Pavarini M; Valdagni R; Vavassori V; Munoz F; Sanguineti G; Di Muzio N; Kirchheiner K; Fiorino C; Cozzarini C
Acta Oncol; 2023 Nov; 62(11):1440-1450. PubMed ID: 37801288
[TBL] [Abstract][Full Text] [Related]
24. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: a pooled prospective evaluation of bowel-associated quality of life.
Seymour ZA; Hamstra DA; Daignault-Newton S; Bosch W; Michalski J; Gay HA; Pinkawa M
BJU Int; 2020 Sep; 126(3):367-372. PubMed ID: 32333714
[TBL] [Abstract][Full Text] [Related]
26. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
27. Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.
Strom TJ; Cruz AA; Figura NB; Shrinath K; Nethers K; Mellon EA; Fernandez DC; Saini AS; Hunt DC; Heysek RV; Wilder RB
Brachytherapy; 2015; 14(6):818-25. PubMed ID: 26452602
[TBL] [Abstract][Full Text] [Related]
28. Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy.
McDonald AM; Baker CB; Popple RA; Shekar K; Yang ES; Jacob R; Cardan R; Kim RY; Fiveash JB
Radiat Oncol; 2014 Jun; 9():129. PubMed ID: 24893842
[TBL] [Abstract][Full Text] [Related]
29. Pelvic bone marrow dose-volume predictors of late lymphopenia following pelvic lymph node radiation therapy for prostate cancer.
Pavarini M; Alborghetti L; Aimonetto S; Maggio A; Landoni V; Ferrari P; Bianculli A; Petrucci E; Cicchetti A; Farina B; Ubeira-Gabellini MG; Salmoiraghi P; Moretti E; Avuzzi B; Giandini T; Munoz F; Magli A; Sanguineti G; Magdalena Waskiewicz J; Rago L; Cante D; Girelli G; Vavassori V; Di Muzio NG; Rancati T; Cozzarini C; Fiorino C
Radiother Oncol; 2024 Jun; 195():110230. PubMed ID: 38503355
[TBL] [Abstract][Full Text] [Related]
30. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
[TBL] [Abstract][Full Text] [Related]
31. Patient-reported quality of life during definitive and postprostatectomy image-guided radiation therapy for prostate cancer.
Diao K; Lobos EA; Yirmibesoglu E; Basak R; Hendrix LH; Barbosa B; Miller SM; Pearlstein KA; Goldin GH; Wang AZ; Chen RC
Pract Radiat Oncol; 2017; 7(2):e117-e124. PubMed ID: 28274402
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
Adkison JB; McHaffie DR; Bentzen SM; Patel RR; Khuntia D; Petereit DG; Hong TS; Tomé W; Ritter MA
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):184-90. PubMed ID: 21163590
[TBL] [Abstract][Full Text] [Related]
33. Acute patient-reported bowel quality of life and rectal bleeding with the combination of prostate external beam radiation, low-dose-rate brachytherapy boost, and SpaceOAR.
Patel AK; Houser C; Benoit R; Smith RP; Beriwal S
Brachytherapy; 2020; 19(4):477-483. PubMed ID: 32331976
[TBL] [Abstract][Full Text] [Related]
34. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity.
Fonteyne V; De Neve W; Villeirs G; De Wagter C; De Meerleer G
Radiother Oncol; 2007 Aug; 84(2):156-63. PubMed ID: 17692976
[TBL] [Abstract][Full Text] [Related]
35. Impact of late anorectal dysfunction on quality of life after pelvic radiotherapy.
Krol R; Smeenk RJ; van Lin EN; Hopman WP
Int J Colorectal Dis; 2013 Apr; 28(4):519-26. PubMed ID: 23080344
[TBL] [Abstract][Full Text] [Related]
36. Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1.
Brown LC; Atherton PJ; Neben-Wittich MA; Wender DB; Behrens RJ; Kozelsky TF; Loprinzi CL; Haddock MG; Martenson JA
Support Care Cancer; 2013 Oct; 21(10):2869-77. PubMed ID: 23748483
[TBL] [Abstract][Full Text] [Related]
37. Quality of Life Changes >10 Years After Postoperative Radiation Therapy After Radical Prostatectomy for Prostate Cancer.
Leufgens F; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):382-388. PubMed ID: 31201895
[TBL] [Abstract][Full Text] [Related]
38. Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer.
Lukka HR; Pugh SL; Bruner DW; Bahary JP; Lawton CAF; Efstathiou JA; Kudchadker RJ; Ponsky LE; Seaward SA; Dayes IS; Gopaul DD; Michalski JM; Delouya G; Kaplan ID; Horwitz EM; Roach M; Pinover WH; Beyer DC; Amanie JO; Sandler HM; Kachnic LA
Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):287-295. PubMed ID: 29913254
[TBL] [Abstract][Full Text] [Related]
39. [Chronic radiation-induced rectal injury after adjuvant radiotherapy for pelvic malignant tumors: report based on a phase 3 randomized clinical trial].
Zhou Y; Huang H; Wan T; Feng YL; Liu JH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):962-968. PubMed ID: 34823296
[No Abstract] [Full Text] [Related]
40. Quality of Life after Post-Prostatectomy Intensity Modulated Radiation Therapy: Pelvic Nodal Irradiation Is Not Associated with Worse Bladder, Bowel, or Sexual Outcomes.
Melotek JM; Liao C; Liauw SL
PLoS One; 2015; 10(10):e0141639. PubMed ID: 26512986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
